EMD Serono Names U.S. CMO

Joseph Leveque, M.D. has been appointed U.S. chief medical officer at EMD Serono, the U.S. biopharmaceutical business of Merck KGaA. Dr. Leveque will be responsible for working with the regulatory, medical and development teams to enhance EMD Serono’s clinical presence in the U.S. and to drive key medical initiatives.
 
Dr. Leveque has more than 20 years of experience in the areas of strategic leadership, advancing medical and clinical programs, as well as life cycle management. Most recently, he served as head of U.S. Medical for Oncology at Bristol-Myers Squibb, where he was responsible for providing strategic leadership and management for marketed and near-term pipeline oncology assets. Dr. Leveque has also held medical affairs leadership positions at Onyx Pharmaceuticals, Inc., Cephalon and Amgen, Inc.
 
“Dr. Leveque’s substantial experience in managing integrated global medical affairs teams will be significant to furthering our specialty care focus in neurology, oncology, fertility, and endocrinology and bringing our pipeline forward,” said Paris Panayiotopoulos, president and managing director of EMD Serono. “In the U.S., Dr. Leveque will collaborate closely with our global medical and R&D organizations, and will play a key role in advancing our commitment to innovation and bringing new therapeutic options to patients, particularly those with difficult to treat diseases.”